London Regional Cancer Center

London, Ontario ON N6A 5W9

1 studies enrolling now · 10 studies all time

What they study most

Advanced or Metastatic Solid Tumors, Borderline Resectable Pancreatic Cancer, Breast Cancer, Glioblastoma Multiforme, HER2 Positive Breast Cancer, Leiomyosarcoma, Liposarcoma, Metastatic Non-Small Cell Lung Cancer, Myelodysplastic Syndromes, Newly Diagnosed Glioblastoma, Non-small-cell Lung Cancer, Pancreatic Cancer

Studies at this site

• Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma — Recruiting now
• Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS — Completed
• A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations — Running, not enrolling
• A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma — Completed
• Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer — Stopped early
• OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer. — Completed
• MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients — Stopped early
• A Study of Nimotuzumab in Combination With Radiation Therapy in Patients With Brain Metastases — Stopped early
• A Study of Nimotuzumab in Combination With External Radiotherapy in Non-Small Cell Lung Cancer — Stopped early
• The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme — Completed